Association of ABCB1 polymorphisms with the efficacy of ondansetron for postoperative nausea and vomiting

Anaesthesia. 2010 Oct;65(10):996-1000. doi: 10.1111/j.1365-2044.2010.06476.x.

Abstract

We investigated whether the 2677G>T/A and 3435C>T polymorphisms of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) affect the efficacy of ondansetron to prevent postoperative nausea and vomiting. One hundred and ninety-eight patients undergoing general anaesthesia were enrolled. Thirty minutes before the end of surgery, 0.1 mg.kg⁻¹ ondansetron was administered intravenously. The incidence of postoperative nausea and vomiting was compared between genotypes in the 2677G>T/A and 3435C>T polymorphisms of ABCB1. The incidence of postoperative nausea and vomiting was lower in patients with the 2677TT genotype (TT vs Non-TT = 25.9% vs 53.0%, p = 0.01) and 3435TT genotype (CC + CT vs TT = 52.6% vs 21.7%, p = 0.01) during the first 2 h after surgery. There were no significant differences in the incidence of postoperative nausea and vomiting between the different genotype groupings during period between 2 and 24 h after surgery. In conclusion, ABCB1 genotypes may be a clinical predictor of responsiveness for ondansetron.

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / genetics*
  • Adult
  • Anesthesia, General / methods
  • Antiemetics / therapeutic use*
  • Cholecystectomy, Laparoscopic
  • Female
  • Genotype
  • Humans
  • Intraoperative Care / methods
  • Male
  • Middle Aged
  • Ondansetron / therapeutic use*
  • Polymorphism, Genetic*
  • Postoperative Nausea and Vomiting / genetics
  • Postoperative Nausea and Vomiting / prevention & control*
  • Prognosis
  • Treatment Outcome

Substances

  • ABCB1 protein, human
  • ATP Binding Cassette Transporter, Subfamily B
  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Antiemetics
  • Ondansetron